Insider Buying: Rein Therapeutics (NASDAQ:RNTX) Director Acquires $24,581.40 in Stock

Posted by Francis Steltz on May 31st, 2026

Rein Therapeutics Inc. (NASDAQ:RNTX – Get Free Report) Director Rickenbach Josef Von bought 23,190 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was purchased at an average cost of $1.06 per share, for a total transaction of $24,581.40. Following the transaction, the director owned 58,014 shares in the company, valued at $61,494.84. The trade was a 66.59% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Rein Therapeutics Stock Performance

Shares of Rein Therapeutics stock opened at $1.11 on Friday. The business’s 50 day simple moving average is $1.32 and its 200 day simple moving average is $1.31. Rein Therapeutics Inc. has a 52-week low of $0.95 and a 52-week high of $2.18. The firm has a market cap of $94.95 million, a PE ratio of -0.58 and a beta of 1.42.

Rein Therapeutics (NASDAQ:RNTX – Get Free Report) last announced its earnings results on Friday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.30. As a group, equities research analysts predict that Rein Therapeutics Inc. will post -1.63 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Rein Therapeutics to a “sell” rating in a research report on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.00.

Get Our Latest Stock Report on RNTX

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Susquehanna International Group LLP acquired a new position in shares of Rein Therapeutics during the 3rd quarter worth approximately $35,000. HRT Financial LP acquired a new position in shares of Rein Therapeutics during the 4th quarter worth approximately $38,000. Chicago Partners Investment Group LLC increased its holdings in shares of Rein Therapeutics by 32.2% during the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after acquiring an additional 10,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Rein Therapeutics during the 2nd quarter worth approximately $68,000. Finally, Jane Street Group LLC acquired a new position in shares of Rein Therapeutics during the 4th quarter worth approximately $72,000. Institutional investors and hedge funds own 90.89% of the company’s stock.

About Rein Therapeutics

(Get Free Report)

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.